Cytek BioSciences Stock Income Statements

Cytek BioSciences Quarterly Income Statements Chart

Quarterly

Annual

Revenue

Gross Profit

Operating Profit

Net Income

Cytek BioSciences Quarterly Income Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30

revenue, net:
product	31,415,000	28,110,000	45,021,000	39,544,000	34,576,000	34,122,000	46,652,000	38,441,000	40,452,000	31,172,000	43,637,000	36,389,000	37,093,000	31,481,000	35,952,000	32,191,000	28,676,000
service	14,187,000	13,347,000	12,455,000	11,956,000	12,041,000	10,738,000	11,581,000	9,559,000	9,241,000	5,916,000	4,699,000	4,088,000	3,066,000	3,583,000	2,942,000	2,185,000	1,732,000
total revenue	45,602,000	41,457,000	57,476,000	51,500,000	46,617,000	44,860,000	58,233,000	48,000,000	49,693,000	37,088,000	48,336,000	40,477,000	40,159,000	35,064,000	38,894,000	34,376,000	30,408,000
yoy	-2.18%	-7.59%	-1.30%	7.29%	-6.19%	20.96%	20.48%	18.59%	23.74%	5.77%	24.28%	17.75%	32.07%
qoq	10.00%	-27.87%	11.60%	10.47%	3.92%	-22.96%	21.32%	-3.41%	33.99%	-23.27%	19.42%	0.79%	14.53%	-9.85%	13.14%	13.05%
cost of sales:
total cost of sales	21,735,000	21,300,000	23,824,000	22,495,000	21,181,000	21,847,000	25,185,000	20,822,000	21,531,000	16,050,000	18,962,000	13,615,000	15,598,000	14,887,000	15,258,000	13,099,000	10,663,000
gross profit	23,867,000	20,157,000	33,652,000	29,005,000	25,436,000	23,013,000	33,048,000	27,178,000	28,162,000	21,038,000	29,374,000	26,862,000	24,561,000	20,177,000	23,636,000	21,277,000	19,745,000
yoy	-6.17%	-12.41%	1.83%	6.72%	-9.68%	9.39%	12.51%	1.18%	14.66%	4.27%	24.28%	26.25%	24.39%
qoq	18.41%	-40.10%	16.02%	14.03%	10.53%	-30.36%	21.60%	-3.49%	33.86%	-28.38%	9.35%	9.37%	21.73%	-14.63%	11.09%	7.76%
gross margin %	52.34%	48.62%	58.55%	56.32%	54.56%	51.30%	56.75%	56.62%	56.67%	56.72%	60.77%	66.36%	61.16%	57.54%	60.77%	61.89%	64.93%
operating expenses:
research and development	8,826,000	9,725,000	9,723,000	9,882,000	10,001,000	9,796,000	10,869,000	11,171,000	12,136,000	9,974,000	9,747,000	8,650,000	8,436,000	8,025,000	7,076,000	6,078,000	6,194,000
sales and marketing	12,134,000	12,509,000	11,874,000	12,429,000	12,268,000	12,543,000	11,561,000	12,076,000	14,367,000	11,145,000	9,029,000	8,810,000	8,431,000	6,960,000	8,304,000	6,553,000	5,576,000
general and administrative	13,531,000	12,898,000	9,069,000	10,942,000	11,694,000	11,408,000	10,755,000	10,351,000	10,786,000	12,081,000	10,514,000	8,042,000	8,585,000	7,549,000	6,939,000	5,749,000	4,164,000
total operating expenses	34,491,000	35,132,000	30,666,000	33,253,000	33,963,000	33,747,000	33,185,000	33,598,000	37,289,000	33,200,000	29,290,000	25,502,000	25,452,000	22,534,000	22,319,000	18,380,000	15,934,000
income from operations	-10,624,000	-14,975,000	2,986,000	-4,248,000	-8,527,000	-10,734,000	-137,000	-6,420,000	-9,127,000	-12,162,000	84,000	1,360,000	-891,000	-2,357,000	1,317,000	2,897,000	3,811,000
yoy	24.59%	39.51%	-2279.56%	-33.83%	-6.57%	-11.74%	-263.10%	-572.06%	924.35%	415.99%	-93.62%	-53.05%	-123.38%
qoq	-29.06%	-601.51%	-170.29%	-50.18%	-20.56%	7735.04%	-97.87%	-29.66%	-24.95%	-14578.57%	-93.82%	-252.64%	-62.20%	-278.97%	-54.54%	-23.98%
operating margin %	-23.30%	-36.12%	5.20%	-8.25%	-18.29%	-23.93%	-0.24%	-13.38%	-18.37%	-32.79%	0.17%	3.36%	-2.22%	-6.72%	3.39%	8.43%	12.53%
other income:
interest expense	-414,000	-291,000	-173,500	-119,000	-134,000	-441,000	-394,000	-595,000	-409,000	-673,000	-687,000	-649,000	-647,000	-590,000	-492,000	-441,000	-433,000
interest income	555,000	508,000	1,031,000	1,433,000	1,416,000	1,359,000	1,448,000	1,622,000	1,201,000	2,143,000	2,626,000	1,584,000	391,000	18,000	18,000	12,000	9,000
other income	3,708,000	3,492,000	491,000	3,091,000	59,000	823,000	3,194,000	1,208,000	1,740,000	1,652,000	2,091,000	-445,000	-254,000	-374,000	-399,000	-393,000	-120,000
total other income	3,849,000	3,709,000	7,337,000	4,405,000	1,341,000	1,741,000	4,248,000	2,235,000	2,532,000	3,122,000	4,030,000	490,000	-510,000	-946,000	-873,000	-822,000	-544,000
income before income taxes	-6,775,000	-11,266,000	10,323,000	157,000	-7,186,000	-8,993,000	4,111,000	-4,185,000	-6,595,000	-9,040,000	4,114,000	1,850,000	-1,401,000	-3,303,000	444,000	2,075,000	3,267,000
(benefit from) benefit from income taxes	-1,192,000		-90,000	-784,000									-699,000	-1,145,000
net income	-5,583,000	-11,402,000	9,643,000	941,000	-10,434,000	-6,169,000	5,503,000	-6,456,000	-4,388,000	-6,807,000	3,718,000	1,626,000	-702,000	-2,158,000	-1,165,000	1,420,000	2,670,000
yoy	-46.49%	84.83%	75.23%	-114.58%	137.78%	-9.37%	48.01%	-497.05%	525.07%	215.43%	-419.14%	14.51%	-126.29%
qoq	-51.03%	-218.24%	924.76%	-109.02%	69.14%	-212.10%	-185.24%	47.13%	-35.54%	-283.08%	128.66%	-331.62%	-67.47%	85.24%	-182.04%	-46.82%
net income margin %	-12.24%	-27.50%	16.78%	1.83%	-22.38%	-13.75%	9.45%	-13.45%	-8.83%	-18.35%	7.69%	4.02%	-1.75%	-6.15%	-3.00%	4.13%	8.78%
net income, basic and diluted	-5,583,000	-11,402,000	-3,915,750	941,000	-10,434,000	-6,169,000
net income per share	-0.04	-0.09	-0.03	0.01	-0.08	-0.05
weighted-average shares used for eps calculation	126,934,294	128,339,481	130,611,330	131,003,744	131,440,486	130,920,971	135,283,044	136,173,278	135,918,707	135,489,194	134,510,831	134,711,701	134,403,059	133,902,523	76,741,858	108,322,433	31,878,762
comprehensive loss:
foreign currency translation adjustment, net of tax	603	-560	-39	101	1,375	-244	307	165	-980	-42	-184	-758	-683	14	327	34	269
unrealized loss on marketable securities	-33	-65			-16				-192
net comprehensive loss	-5,013	-12,027			-9,075	-6,448			-5,560	-6,697
benefit from income taxes		136,000			3,248,000	-2,824,000	-1,392,000	2,271,000	-2,207,000	-2,233,000	396,000	224,000			1,609,000	655,000	597,000
comprehensive income:
unrealized gain on marketable securities			-47	195		-35	-3	15		152
net comprehensive income			9,557	1,237			5,807	-6,276			3,551	868	-1,385	-2,144	-838	1,454	2,939
less: net income allocated to noncontrolling interests											70,250	40,000	104,000	137,000
net income attributable to common stockholders, basic and diluted							5,503,000	-6,456,000	-4,388,000	-6,807,000	3,529,000	1,666,000	-598,000	-2,021,000		346,000
net income attributable to common stockholders per share, basic							0.04	-0.05			0.03	0.01	0	-0.02
net income attributable to common stockholders per share, diluted							0.04	-0.05			0.03	0.01	0	-0.02
net income attributable to common stockholders per share, basic and diluted									-0.03	-0.05
less: net income allocated to participating securities															1,191,000	-1,074,000	-2,670,000
net income attributable to common stockholders per share diluted

We provide you with 20 years income statements for Cytek BioSciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Cytek BioSciences stock. Explore the full financial landscape of Cytek BioSciences stock with our expertly curated income statements.

The information provided in this report about Cytek BioSciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.